Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


'Welcome home': Stromedix buy brings fibrosis drug back to Biogen

This article was originally published in Scrip

Executive Summary

Biogen Idec has agreed to acquire five-year-old, privately-held Stromedix Inc for $75 million upfront and up to $487.5 million in milestones. But there is a twist to the buyout, as the research programme at the heart of the startup – which is also behind a candidate for idiopathic pulmonary fibrosis (IPF) - began at Biogen.


Related Content

Arrakis Pivots From Platform To Pipeline With $75m For RNA-Targeting Small Molecules
With Serial Entrepreneur At Its Helm, Arrakis Raises $38m To Target RNA With Small Molecules


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts